Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma

Amyn Mohammed Rojiani, Lingyun Li, Leroy Rise, Dietmar W. Siemann

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Combretastatin A4 disodium phosphate (CA4DP) was evaluated in a xenograft model of AIDS-KS. KS xenografts were highly vascular, showing brisk mitotic activity, focal areas of necrosis, and intervening fibrovascular septae. Neoplastic cells were large or spindle-shaped, with vesicular nuclei and modest pleomorphism. Multiple junctions, microvillous-like projections, abortive lumina and rare Weibel Palade bodies were revealed by electron microscopy. Treatment with CA4DP (100 mg/kg) resulted in rapid onset of vascular effects that within 4 h resulted in an almost complete vascular shutdown in these tumors. Histological evaluation showed morphological damage within a few hours after treatment, followed by extensive necrosis which increased to ∼ 90% by 24 h. At this time, viable tumor cells were evident only at the periphery of the tumor. These findings demonstrate not only the marked susceptibility of the KS model to CA4DP but also its potential application in studies related to the pathogenesis and therapy of AIDS-KS.

Original languageEnglish (US)
Pages (from-to)98-105
Number of pages8
JournalActa Oncologica
Volume41
Issue number1
DOIs
StatePublished - Apr 20 2002
Externally publishedYes

Fingerprint

Kaposi's Sarcoma
Heterografts
Blood Vessels
Acquired Immunodeficiency Syndrome
Necrosis
Weibel-Palade Bodies
Neoplasms
Electron Microscopy
fosbretabulin
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. / Rojiani, Amyn Mohammed; Li, Lingyun; Rise, Leroy; Siemann, Dietmar W.

In: Acta Oncologica, Vol. 41, No. 1, 20.04.2002, p. 98-105.

Research output: Contribution to journalArticle

@article{1ad8dcdee0c74a3587b6cc9927314647,
title = "Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma",
abstract = "Combretastatin A4 disodium phosphate (CA4DP) was evaluated in a xenograft model of AIDS-KS. KS xenografts were highly vascular, showing brisk mitotic activity, focal areas of necrosis, and intervening fibrovascular septae. Neoplastic cells were large or spindle-shaped, with vesicular nuclei and modest pleomorphism. Multiple junctions, microvillous-like projections, abortive lumina and rare Weibel Palade bodies were revealed by electron microscopy. Treatment with CA4DP (100 mg/kg) resulted in rapid onset of vascular effects that within 4 h resulted in an almost complete vascular shutdown in these tumors. Histological evaluation showed morphological damage within a few hours after treatment, followed by extensive necrosis which increased to ∼ 90{\%} by 24 h. At this time, viable tumor cells were evident only at the periphery of the tumor. These findings demonstrate not only the marked susceptibility of the KS model to CA4DP but also its potential application in studies related to the pathogenesis and therapy of AIDS-KS.",
author = "Rojiani, {Amyn Mohammed} and Lingyun Li and Leroy Rise and Siemann, {Dietmar W.}",
year = "2002",
month = "4",
day = "20",
doi = "10.1080/028418602317314136",
language = "English (US)",
volume = "41",
pages = "98--105",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma

AU - Rojiani, Amyn Mohammed

AU - Li, Lingyun

AU - Rise, Leroy

AU - Siemann, Dietmar W.

PY - 2002/4/20

Y1 - 2002/4/20

N2 - Combretastatin A4 disodium phosphate (CA4DP) was evaluated in a xenograft model of AIDS-KS. KS xenografts were highly vascular, showing brisk mitotic activity, focal areas of necrosis, and intervening fibrovascular septae. Neoplastic cells were large or spindle-shaped, with vesicular nuclei and modest pleomorphism. Multiple junctions, microvillous-like projections, abortive lumina and rare Weibel Palade bodies were revealed by electron microscopy. Treatment with CA4DP (100 mg/kg) resulted in rapid onset of vascular effects that within 4 h resulted in an almost complete vascular shutdown in these tumors. Histological evaluation showed morphological damage within a few hours after treatment, followed by extensive necrosis which increased to ∼ 90% by 24 h. At this time, viable tumor cells were evident only at the periphery of the tumor. These findings demonstrate not only the marked susceptibility of the KS model to CA4DP but also its potential application in studies related to the pathogenesis and therapy of AIDS-KS.

AB - Combretastatin A4 disodium phosphate (CA4DP) was evaluated in a xenograft model of AIDS-KS. KS xenografts were highly vascular, showing brisk mitotic activity, focal areas of necrosis, and intervening fibrovascular septae. Neoplastic cells were large or spindle-shaped, with vesicular nuclei and modest pleomorphism. Multiple junctions, microvillous-like projections, abortive lumina and rare Weibel Palade bodies were revealed by electron microscopy. Treatment with CA4DP (100 mg/kg) resulted in rapid onset of vascular effects that within 4 h resulted in an almost complete vascular shutdown in these tumors. Histological evaluation showed morphological damage within a few hours after treatment, followed by extensive necrosis which increased to ∼ 90% by 24 h. At this time, viable tumor cells were evident only at the periphery of the tumor. These findings demonstrate not only the marked susceptibility of the KS model to CA4DP but also its potential application in studies related to the pathogenesis and therapy of AIDS-KS.

UR - http://www.scopus.com/inward/record.url?scp=0036221310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036221310&partnerID=8YFLogxK

U2 - 10.1080/028418602317314136

DO - 10.1080/028418602317314136

M3 - Article

VL - 41

SP - 98

EP - 105

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 1

ER -